Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.
This study used the guinea pig keratoconjunctivitis model to examine the importance of route of administration (mucosal versus parenteral), frequency and timing of immunization (primary versus boosting immunization), and form of antigen given (live attenuated vaccine strain versus O-antigen-protein conjugate) on the production of protective immunity against Shigella infection. Since local immune response to the lipopolysaccharide (LPS) O-antigen of Shigella spp. is thought to be important for protection against disease, O-antigen-specific antibody-secreting cells (ASC) in the spleen and regional lymph nodes of immunized animals were measured by using an ELISPOT assay. Results indicated that protective efficacy was associated with a strong O-antigen-specific ASC response, particularly in the superficial ventral cervical lymph nodes draining the conjunctivae. In naive animals, a strong ASC response in the cervical lymph nodes and protection against challenge were detected only in animals that received a mucosal immunization. Protection in these animals was increased by a boosting mucosal immunization. While parenteral immunization alone with an O-antigen-protein conjugate vaccine did not protect naive animals against challenge, a combined parenteral-mucosal regimen elicited enhanced protection without the addition of a boosting immunization. Although O-antigen-specific serum immunoglobulin A titers were significantly higher in animals receiving a mucosal immunization, there was no apparent correlation between levels of serum antibody and protection against disease.
Hartman
A B
AB
Department of Enteric Infections, Walter Reed Army Institute of Research, Washington, D.C. 20307-5100.
Van de Verg
L L
LL
Collins
H H
HH
Tang
D B
DB
Bendiuk
N O
NO
Taylor
D N
DN
Powell
C J
CJ
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000921:Antibody-Producing Cells / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004405:Dysentery, Bacillary / Q000276:immunology / Q000517:prevention & control*; D006168:Guinea Pigs; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000097:blood; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007639:Keratoconjunctivitis, Infectious / Q000276:immunology / Q000517:prevention & control*; D008198:Lymph Nodes / Q000276:immunology; D009092:Mucous Membrane / Q000276:immunology; D019081:O Antigens; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage; D012763:Shigella flexneri / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D014613:Vaccines, Attenuated / Q000008:administration & dosage; D014614:Vaccines, Synthetic / Q000008:administration & dosage
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007070:Immunoglobulin A; D019081:O Antigens; D011135:Polysaccharides, Bacterial; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic